Beijing-based Chinese venture capital firm Kaiwu Capital disclosed in a U.S. Securities and Exchange Commission filing that it has raised US$98 million for its debut fund.
Beijing-based private medical services provider iKang Goubin Healthcare Group has filed with the U.S. Securities and Exchange Commission for an initial public offering (IPO) on NASDAQ to raise as much as US$150 million, according to a regulatory filing of the company.
NewQuest Capital Partners and Singapore’s GIC Private Ltd. will make a partial exit from Beijing-based private medical services provider iKang Guobin Healthcare Group as the company seeks to raise as much as US$175 million through a U.S. IPO, according to a regulatory filing of iKang.
Changsha, Hunan province-based eye hospital group Aier Eye Hospital Group plans to commit RMB100 million ($16 million) to Beijing Huatai Ruilian M&A Fund, according to a company announcement.
Changsha, Hunan province-based Chinese eye hospital operator Aier Eye Hospital Group has launched an M&A fund with Shenzhen Qianhai Orient Venture Financial Holding to bringing about consolidation in the ophthalmology industry, according to Chinese media reports.
Morgan Stanley Private Equity Asia (MSPEA) is to sale 120 million shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd., according to media reports.
Shanghai-based BVCF, a growth capital-focused private equity fund specializing in the life sciences industry, has completed a final close of its third fund, raising a total of US$200 million, according to media reports.
Beijing-based private medical services provider iKang Guobin Healthcare Group has raised US$153 million by offering 10.9 million shares at US$14 per share on the NASDAQ, according to an announcement on the exchange’s website.
Washington, D.C.-based global private equity firm The Carlyle Group is the bidder who has offered a higher price to privatize NASDAQ-listed Chinese hospital operator Chindex International, Inc., according to Chinese media reports.
Beijing-based dental service provider Arrail Dental Clinic has received US$70 million series C financing led by New Horizon Capital, according to a company announcement.
NASDAQ-listed Chinese high-end hospital operator Chindex International, Inc. says that it has entered into an amended merger agreement with TPG Capital, Shanghai Fosun Pharmaceutical and the company’s CEO Roberta Lipson to take the company private for US$24 per share in cash, according to a company announcement.
The Asian Development Bank (ADB) has agreed to invest up to US$60 million in OrbiMed Asia Partners, a private equity fund focused on the healthcare industry in Asia, according to a release by the regional development bank.
Shanghai-based online pharmacy platform J1.com has received US$50 million series A financing from Shanghai International Group Venture Capital Co., Ltd. (SIGVC), J1.com’s official Weibo account confirms.
Chinese medical device maker Shanghai Aohua Photoelectricity Endoscope Co., Ltd. has received close to US$16 million series B financing from Legend Capital last month, according to Chinese media reports.
Chinese bone medical equipment manufacturer Shanghai Sanyou Medical Equipment Co. Ltd. has received a new round of financing from Qiming Venture Partners and Taifu Capital, according to a joint announcement.
Beijing-based private equity and venture capital firm CDH Investments has teamed up with Chinese pharmaceutical firm China Grand Pharmaceutical and Healthcare Holdings to acquire 71.25% of Shanghai Weicon Optical Co., Ltd. for a total of US$78.75 million, according to an announcement.
German healthcare company the Artemon Group has signed a strategic agreement with the Shanghai Waigaoqiao Free Trade Zone Development Co., Ltd. to establish the first wholly foreign-owned hospital in mainland China, according to official Chinese news reports.
Shanghai-based biotech drug company ZAI Lab has received US$30 million Series A financing led by Qiming Venture Partners, according to ZAI Lab’s official announcement. KPCB, Sequoia Capital and TF Capital also participate in this round of financing.
China’s largest online healthcare community portal DXY, which is short for its Chinese name Ding Xiang Yuan, has received US$70 million series C financing from Tencent Holdings Limited, according to an official announcement. The details of the investment are not disclosed, but Tencent will take a "small proportion" of the company, according to the statement.
Healthcare-dedicated investment firm OrbiMed Advisors has closed a US$325 million Asian fund, above its US$300 million target and much larger than its first Asian vehicle with US$188 million launched in 2008, according to media reports. The new fund is to focus on investing in drug developers, diagnostics firms and medical device manufacturers in the region.
Sino-French private equity firm Cathay Capital Private Equity says it has invested RMB150 million (US$24.5 million) in traditional Chinese medicine firm Kunming Shenghuo Pharmaceutical Group Co., Ltd., according to a company announcement. The deal was closed at the end of June. The investment is from Cathay Capital II and the Sino-French Fund for small and medium enterprises (SMEs)
Twenty-four domestic and international investors and institutions plan to sign an agreement next Monday with the government of Shenzhen, to invest a total of RMB8 billion (US$1.3B) to build private and public hospitals in the city, according to Chinese media reports. The planned investment is part of the drive initiated by the Chinese government since the 2009 healthcare reform to attract more private capital into the sector.
Chinese smartphone maker Xiaomi Inc.‘s venture capital arm has agreed to invest US$25 million in Chinese health products maker Andon Health Company Limited, according to a regulatory filing. Tianjin-based Andon Health will establish a new entity called iHealth Inc. in Cayman Island, and inject its related global businesses in electronic and smart health device division iHealth into the new platform. Xiaomi Ventures Limited will hold a 20% stake of iHealth Inc. The two will develop new health products and services …
U.S. private equity giant Blackstone Group L.P. has agreed to acquire a stake in SuZhou city-based Chinese orthopedic medical instruments maker Xinrong Best Medical Instrument Co. Ltd., according to a company statement. Deal terms were not disclosed, but media reports have put the investment at over US$100 million.
London-based US$46 billion-under-management private equity firm CVC Capital Partners is selling 186 million shares in China’s Jintian Pharmaceutical Group for as much as HK$620 million (US$79.95 million), according to media reports. CVC is selling the shares in a range of HK$3.29 to HK$3.34 apiece, representing a 3.5% to 4.9% discount to the share’s last closing price.
Hangzhou-based online healthcare service provider GuaHao.com has received over US$100 million investment by Chinese Internet services giant Tencent Holdings Limited, according to a company announcement. This is the largest single investment in China’s Internet healthcare sector. No further details of the investment were disclosed. But GuaHao.com will continue to operate independently, says the statement. The investment is part of a wider strategic partnership to be established between the two parties. GuaHao.com will incorporate Tencent’s products such as its Wechat app …
Salisbury, U.K.-based molecular diagnostic testing firm Enigma Diagnostics Ltd. says that Sailing Capital Management has agreed to invest US$50 million to help support the British company’s global expansion, according to a company announcement. Sailing Capital is an investment firm controlled by Shanghai International Group (SIG). Last December, it launched a RMB5 billion buyout fund to focus on cross-border deals, and a RMB5 billion ($821m) buyout fund.
Yantai, Shandong Province-based Chinese drug-maker Luye Pharma Group Ltd., backed by Chinese private equity investors, has agreed to acquire the remaining 42.02% stake of Beijing Jialin Pharmaceutical Co., Ltd. it doesn’t already own, according to a regulatory filing submitted on October 24. Luye Pharma, with shareholders including CDH Investments, CITIC Private Equity and New Horizon Capital, just completed a Hong Kong IPO in July raising a total of US$764 million.
China’s medical technology (medtech) market will grow at 14% compound annual growth rate from 2013 to 2020 to reach US$55 million in total size by 2020, making it the world’s second largest medtech market, says a new report released by The Boston Consulting Group. China’s healthcare reform has significantly transformed the healthcare system, including changing regulatory policies, intensifying pricing pressure, and broadening reimbursement coverage.
San Francisco-based veterinary drug developer Jaguar Animal Health Inc., backed by China-focused life sciences private equity investor BVCF, is planning an IPO on the NASDAQ to raise as much as US$54 million, according to a regulatory filing. The company is planing to sell five million shares at an indicative price range of of US$7 to US$9 apiece.
NASDAQ-listed Chinese high-end hospital operator Chindex International, Inc. says that it has completed a go-private transaction by an investor consortium for US$24 per share in cash, according to a company announcement. The company has been acquired by Healthy Harmony Holdings, L.P., an affiliate of TPG Capital, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Chindex’s CEO, Roberta Lipson.